Научно-практический журнал
[About us] Journal 'Cytokines & Inflammation'

197376, Санкт-Петербург, ул. Акад. Павлова, д. 12,
Институт экспериментальной медицины РАМН
Тел.: (812) 543 52 14, +7 921 984 11 30, +7 921 909 55 49
Факс: (812) 543 52 14
Web: cytokines.ru


Year 2016
Number 1 Number 2

About journal

Current year


Rules for authors

Contact us


Site map

Our partners:


Русский языкEnglish language
Site map Contact us

Contents | Next article | Previous article

Journal 'Cytokines & inflammation', 2016, No. 1

Order this issue

Order PDF of this article


Number 1'2016

Cytokine-induced hepcidin expression in pathogenesis of anemia in chronic diseases and tumors as the target for new treatment strategies

O.A. Smirnov, O.N. Smirnova

Anemia as a complication of many chronic diseases and tumors has a multifactorial origin. But the most common link in anemia pathogenesis is a participation of pro-inflammatory cytokines (TNFα, IL-1, IL-6, IFNγ et al.), which induce expression of the iron regulatory hormone hepcidin by hepatocytes, inhibit erythropoietin production by the kidneys and reduce erythrocytes precursors sensitivity to it, suppress differentiation, proliferation of haematopoietic elements, and initiate their apoptosis. Hepcidin limits iron absorption and accessibility, and stimulates its redistribution from functional to reserve pool. New treatment strategies in pathogenetic therapy in patients with anemia with chronic diseases and tumors are based on anti-hepcidin drugs presented by antibodies to hormone, inhibitors and blockers of its expression including erythroferrone, hormone of erythroblasts. (Cytokines and Inflammation. 2016. Vol. 15. № 1. P. 22–27.)

Keywords: anemia in chronic diseases and tumors, pro-inflammatory cytokines, hepcidin, anti-hepcidin treatment.

Contents | Next article | Previous article

© 2007-2017 Cytokines and inflammation